1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE , >95% , 28289-54-5

CAS NO.：28289-54-5

Empirical Formula: C12H15N

Molecular Weight: 173.25

MDL number: MFCD00006120

EINECS: 248-939-7

PRODUCT Properties

• Melting point: aprox. 36°C
• Boiling point: 128-132 °C12 mm Hg(lit.)
• Density: 1.001±0.06 g/cm3(Predicted)
• storage temp.: Inert atmosphere,Room Temperature
• solubility: Chloroform (Slightly), Dichloromethane (Slightly), Ethyl Acetate (Slightly)
• form: Solid
• pka: 8.66±0.40(Predicted)
• color: Pale Yellow to Light Yellow
• Merck: 13,6319
• Stability: Stable. Incompatible with strong oxidizing agents.

Description and Uses

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine is a dopaminergic neurotoxin that reportedly causes a severe and irreversible Parkinsonian condition in humans and monkeys.

Safety

• Symbol(GHS): GHS08,GHS06
• Signal word: Danger
• Hazard statements: H370-H301
• Precautionary statements: P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P307+P311-P321-P405-P501
• Hazard Codes: T
• Risk Statements: 25-39/23/24/25
• Safety Statements: 45
• RIDADR: UN 2811 6.1/PG 2
• WGK Germany: 3
• RTECS: UT8358900
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 28289-54-5(Hazardous Substances Data)
• Toxicity: Human toxicity originally discovered when it was an unexpected by-product from the illicit synthesis of a heroin substitute (i.e., meperidine analog). Currently used experimentally as the primary animal model for the study of Parkinson’s disease. MPTP is a neurotoxicant that is activated to 1-methyl-4-phenylpyridinium ion (MPP1) by the actions of monoamine oxidase B located in the mitochondria of brain astrocytes. The MPP1 is then transported into dopamine, and to a lesser extent, other monoaminergic neurons. Once inside these dopamine neurons in the substantia nigra, it destroys these neurons by mechanisms that may involve an oxidative cascade and/or inhibition of electron transport. Intoxication causes a parkinsonism syndrome almost identical in signs and symptoms to Parkinson’s disease, including rigidity, bradykinesia, tremor, and postural instability. In the event of known ingestion, immediate (but not delayed) administration of a monoamine oxidase inhibitor (especially one selective for MAO-B like deprenyl) and dopamine uptake inhibitor can be therapeutic.